Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis

Changcun Guo, Guanya Guo, Xia Zhou, Yu Chen, Zheyi Han, Caifeng Yang, Shimin Zhao, Hongling Su, Zhexiong Lian, Patrick S Leung, M. Eric Gershwin, Xinmin Zhou, Ying Han

Research output: Contribution to journalArticle

Abstract

Background & Aims: Peripheral blood stem cells (PBSCs) mobilized with colony-stimulating factor can promote liver regeneration and increase liver function in patients with liver diseases. However, the long-term effects of stem cell treatments on survival and risk of hepatocellular carcinoma (HCC) in patients with cirrhosis have not been determined. We investigated the long-term effects of autologous stem cell transplantation and risk of HCC in patients with cirrhosis. Methods: We performed a retrospective analysis of 2 cohorts of patients with decompensated cirrhosis who received transplantations of autologous PBSCs (n = 282) or standard medical treatment (SMT, n = 286) in China from January 1, 2006, through December 31, 2016. Patients were followed up until death or liver transplantation. Mortality data were obtained by case records and confirmed by telephone calls. Survival time was calculated and HCC was confirmed by computed tomography or ultrasound. We used propensity score matching to adjust the differences between the 2 groups. Survival and incidence of HCC were analyzed and Cox proportional hazard regression was used to determine the prognostic factors. Results: After propensity score matching, time of survival was significantly higher in the PBSC group than the SMT group (P =.001). The adjusted rate of 5-year survival was 71.2% in the PBSC group and 52.1% in the SMT group. The overall incidence of HCC did not differ significantly between the PBSC and SMT groups (21.1% vs 20.4%; P =.999). Significant improvement of liver functions was observed at 1 year, 2 years, 3 years, and 5 years after PBSC transplantation compared with the SMT group. Conclusions: In a long-term analysis of patients with decompensated cirrhosis, autologous transplants of PBSCs significantly improved long-term survival compared with a control group. PBSC transplant did not appear to increase the risk of HCC.

Original languageEnglish (US)
Pages (from-to)1175-1182.e2
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number6
DOIs
StatePublished - May 1 2019

Fingerprint

Peripheral Blood Stem Cell Transplantation
Hepatocellular Carcinoma
Fibrosis
Survival
Propensity Score
Colony-Stimulating Factors
Liver Regeneration
Liver
Incidence
Autografts
Stem Cell Transplantation
Telephone
Liver Transplantation
Peripheral Blood Stem Cells
Liver Diseases
China
Cohort Studies
Stem Cells
Tomography
Transplants

Keywords

  • Cancer
  • Liver Regeneration
  • Retrospective Study
  • Stem Cell Therapy

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis. / Guo, Changcun; Guo, Guanya; Zhou, Xia; Chen, Yu; Han, Zheyi; Yang, Caifeng; Zhao, Shimin; Su, Hongling; Lian, Zhexiong; Leung, Patrick S; Gershwin, M. Eric; Zhou, Xinmin; Han, Ying.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 6, 01.05.2019, p. 1175-1182.e2.

Research output: Contribution to journalArticle

Guo, C, Guo, G, Zhou, X, Chen, Y, Han, Z, Yang, C, Zhao, S, Su, H, Lian, Z, Leung, PS, Gershwin, ME, Zhou, X & Han, Y 2019, 'Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis', Clinical Gastroenterology and Hepatology, vol. 17, no. 6, pp. 1175-1182.e2. https://doi.org/10.1016/j.cgh.2018.10.034
Guo, Changcun ; Guo, Guanya ; Zhou, Xia ; Chen, Yu ; Han, Zheyi ; Yang, Caifeng ; Zhao, Shimin ; Su, Hongling ; Lian, Zhexiong ; Leung, Patrick S ; Gershwin, M. Eric ; Zhou, Xinmin ; Han, Ying. / Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis. In: Clinical Gastroenterology and Hepatology. 2019 ; Vol. 17, No. 6. pp. 1175-1182.e2.
@article{d419d65c545647f7bcbb64741216948e,
title = "Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis",
abstract = "Background & Aims: Peripheral blood stem cells (PBSCs) mobilized with colony-stimulating factor can promote liver regeneration and increase liver function in patients with liver diseases. However, the long-term effects of stem cell treatments on survival and risk of hepatocellular carcinoma (HCC) in patients with cirrhosis have not been determined. We investigated the long-term effects of autologous stem cell transplantation and risk of HCC in patients with cirrhosis. Methods: We performed a retrospective analysis of 2 cohorts of patients with decompensated cirrhosis who received transplantations of autologous PBSCs (n = 282) or standard medical treatment (SMT, n = 286) in China from January 1, 2006, through December 31, 2016. Patients were followed up until death or liver transplantation. Mortality data were obtained by case records and confirmed by telephone calls. Survival time was calculated and HCC was confirmed by computed tomography or ultrasound. We used propensity score matching to adjust the differences between the 2 groups. Survival and incidence of HCC were analyzed and Cox proportional hazard regression was used to determine the prognostic factors. Results: After propensity score matching, time of survival was significantly higher in the PBSC group than the SMT group (P =.001). The adjusted rate of 5-year survival was 71.2{\%} in the PBSC group and 52.1{\%} in the SMT group. The overall incidence of HCC did not differ significantly between the PBSC and SMT groups (21.1{\%} vs 20.4{\%}; P =.999). Significant improvement of liver functions was observed at 1 year, 2 years, 3 years, and 5 years after PBSC transplantation compared with the SMT group. Conclusions: In a long-term analysis of patients with decompensated cirrhosis, autologous transplants of PBSCs significantly improved long-term survival compared with a control group. PBSC transplant did not appear to increase the risk of HCC.",
keywords = "Cancer, Liver Regeneration, Retrospective Study, Stem Cell Therapy",
author = "Changcun Guo and Guanya Guo and Xia Zhou and Yu Chen and Zheyi Han and Caifeng Yang and Shimin Zhao and Hongling Su and Zhexiong Lian and Leung, {Patrick S} and Gershwin, {M. Eric} and Xinmin Zhou and Ying Han",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.cgh.2018.10.034",
language = "English (US)",
volume = "17",
pages = "1175--1182.e2",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis

AU - Guo, Changcun

AU - Guo, Guanya

AU - Zhou, Xia

AU - Chen, Yu

AU - Han, Zheyi

AU - Yang, Caifeng

AU - Zhao, Shimin

AU - Su, Hongling

AU - Lian, Zhexiong

AU - Leung, Patrick S

AU - Gershwin, M. Eric

AU - Zhou, Xinmin

AU - Han, Ying

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background & Aims: Peripheral blood stem cells (PBSCs) mobilized with colony-stimulating factor can promote liver regeneration and increase liver function in patients with liver diseases. However, the long-term effects of stem cell treatments on survival and risk of hepatocellular carcinoma (HCC) in patients with cirrhosis have not been determined. We investigated the long-term effects of autologous stem cell transplantation and risk of HCC in patients with cirrhosis. Methods: We performed a retrospective analysis of 2 cohorts of patients with decompensated cirrhosis who received transplantations of autologous PBSCs (n = 282) or standard medical treatment (SMT, n = 286) in China from January 1, 2006, through December 31, 2016. Patients were followed up until death or liver transplantation. Mortality data were obtained by case records and confirmed by telephone calls. Survival time was calculated and HCC was confirmed by computed tomography or ultrasound. We used propensity score matching to adjust the differences between the 2 groups. Survival and incidence of HCC were analyzed and Cox proportional hazard regression was used to determine the prognostic factors. Results: After propensity score matching, time of survival was significantly higher in the PBSC group than the SMT group (P =.001). The adjusted rate of 5-year survival was 71.2% in the PBSC group and 52.1% in the SMT group. The overall incidence of HCC did not differ significantly between the PBSC and SMT groups (21.1% vs 20.4%; P =.999). Significant improvement of liver functions was observed at 1 year, 2 years, 3 years, and 5 years after PBSC transplantation compared with the SMT group. Conclusions: In a long-term analysis of patients with decompensated cirrhosis, autologous transplants of PBSCs significantly improved long-term survival compared with a control group. PBSC transplant did not appear to increase the risk of HCC.

AB - Background & Aims: Peripheral blood stem cells (PBSCs) mobilized with colony-stimulating factor can promote liver regeneration and increase liver function in patients with liver diseases. However, the long-term effects of stem cell treatments on survival and risk of hepatocellular carcinoma (HCC) in patients with cirrhosis have not been determined. We investigated the long-term effects of autologous stem cell transplantation and risk of HCC in patients with cirrhosis. Methods: We performed a retrospective analysis of 2 cohorts of patients with decompensated cirrhosis who received transplantations of autologous PBSCs (n = 282) or standard medical treatment (SMT, n = 286) in China from January 1, 2006, through December 31, 2016. Patients were followed up until death or liver transplantation. Mortality data were obtained by case records and confirmed by telephone calls. Survival time was calculated and HCC was confirmed by computed tomography or ultrasound. We used propensity score matching to adjust the differences between the 2 groups. Survival and incidence of HCC were analyzed and Cox proportional hazard regression was used to determine the prognostic factors. Results: After propensity score matching, time of survival was significantly higher in the PBSC group than the SMT group (P =.001). The adjusted rate of 5-year survival was 71.2% in the PBSC group and 52.1% in the SMT group. The overall incidence of HCC did not differ significantly between the PBSC and SMT groups (21.1% vs 20.4%; P =.999). Significant improvement of liver functions was observed at 1 year, 2 years, 3 years, and 5 years after PBSC transplantation compared with the SMT group. Conclusions: In a long-term analysis of patients with decompensated cirrhosis, autologous transplants of PBSCs significantly improved long-term survival compared with a control group. PBSC transplant did not appear to increase the risk of HCC.

KW - Cancer

KW - Liver Regeneration

KW - Retrospective Study

KW - Stem Cell Therapy

UR - http://www.scopus.com/inward/record.url?scp=85064324068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064324068&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.10.034

DO - 10.1016/j.cgh.2018.10.034

M3 - Article

C2 - 30613001

AN - SCOPUS:85064324068

VL - 17

SP - 1175-1182.e2

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 6

ER -